Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Yeisen, Rafal A. H.
Bjornestad, Jone
Joa, Inge
Johannessen, Jan Olav
and
Opjordsmoen, Stein
2017.
Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study.
BMC Psychiatry,
Vol. 17,
Issue. 1,
Lawrie, Stephen M.
2018.
Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective.
Therapeutic Advances in Psychopharmacology,
Vol. 8,
Issue. 11,
p.
319.
Russo, Patrizia
Prinzi, Giulia
Proietti, Stefania
Lamonaca, Palma
Frustaci, Alessandra
Boccia, Stefania
Amore, Rosarita
Lorenzi, Maria
Onder, Graziano
Marzetti, Emanuele
Valdiglesias, Vanessa
Guadagni, Fiorella
Valente, Maria Giovanna
Cascio, Gerland Lo
Fraietta, Sara
Ducci, Giuseppe
and
Bonassi, Stefano
2018.
Shorter telomere length in schizophrenia: Evidence from a real-world population and meta-analysis of most recent literature.
Schizophrenia Research,
Vol. 202,
Issue. ,
p.
37.
Upthegrove, Rachel
and
A., S.
2018.
Delusions in Context.
p.
1.
Ringen, Petter Andreas
Faerden, Ann
Antonsen, Bjørnar
Falk, Ragnhild S.
Mamen, Asgeir
Rognli, Eline B.
Solberg, Dag K.
Andreassen, Ole A.
and
Martinsen, Egil W.
2018.
Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments.
Nordic Journal of Psychiatry,
Vol. 72,
Issue. 4,
p.
296.
Dickerson, Faith B
2018.
Excess mortality in severe mental illness: more questions than answers.
The Lancet Psychiatry,
Vol. 5,
Issue. 8,
p.
610.
Haddad, Peter M.
and
Correll, Christoph U.
2018.
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.
Therapeutic Advances in Psychopharmacology,
Vol. 8,
Issue. 11,
p.
303.
Leucht, Stefan
2018.
Is there compelling evidence that schizophrenia long‐term treatment guidelines should be changed?.
World Psychiatry,
Vol. 17,
Issue. 2,
p.
166.
Davidson, Michael
2018.
The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia.
Dialogues in Clinical Neuroscience,
Vol. 20,
Issue. 3,
p.
215.
Correll, Christoph U.
Rubio, Jose M.
and
Kane, John M.
2018.
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?.
World Psychiatry,
Vol. 17,
Issue. 2,
p.
149.
Schneider-Thoma, Johannes
Efthimiou, Orestis
Huhn, Maximilian
Krause, Marc
Reichelt, Leonie
Röder, Hannah
Davis, John M
Salanti, Georgia
and
Leucht, Stefan
2018.
Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials.
The Lancet Psychiatry,
Vol. 5,
Issue. 8,
p.
653.
Faden, Justin
2019.
How do we select an antipsychotic for those with schizophrenia?.
Expert Opinion on Pharmacotherapy,
Vol. 20,
Issue. 18,
p.
2195.
Firth, Joseph
Rosenbaum, Simon
Galletly, Cherrie
Siddiqi, Najma
Stubbs, Brendon
Killackey, Eoin
Koyanagi, Ai
and
Siskind, Dan
2019.
Protecting physical health in people with mental illness – Authors' reply.
The Lancet Psychiatry,
Vol. 6,
Issue. 11,
p.
890.
Carolan, Aoife
Keating, Dolores
Strawbridge, Judith
and
Ryan, Cristin
2019.
Optimising prescribing for patients with severe mental illness: the need for criteria.
Evidence Based Mental Health,
Vol. 22,
Issue. 4,
p.
139.
Siskind, Dan
and
Kisely, Steve
2019.
Balancing body and mind: selecting the optimal antipsychotic.
The Lancet,
Vol. 394,
Issue. 10202,
p.
900.
de Mooij, Liselotte D.
Kikkert, Martijn
Theunissen, Jan
Beekman, Aartjan T.F.
de Haan, Lieuwe
Duurkoop, Pim W.R.A.
Van, Henricus L.
and
Dekker, Jack J.M.
2019.
Dying Too Soon: Excess Mortality in Severe Mental Illness.
Frontiers in Psychiatry,
Vol. 10,
Issue. ,
de Bartolomeis, Andrea
Avagliano, Camilla
Vellucci, Licia
D’Ambrosio, Luigi
Manchia, Mirko
D’Urso, Giordano
Buonaguro, Elisabetta Filomena
and
Iasevoli, Felice
2019.
Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia.
Neuroscience & Biobehavioral Reviews,
Vol. 107,
Issue. ,
p.
795.
Vermeulen, Jentien M
van Rooijen, Geeske
van de Kerkhof, Marita P J
Sutterland, Arjen L
Correll, Christoph U
and
de Haan, Lieuwe
2019.
Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years.
Schizophrenia Bulletin,
Vol. 45,
Issue. 2,
p.
315.
Lambert, Martin
Karow, Anne
Gallinat, Jürgen
Lüdecke, Daniel
Kraft, Vivien
Rohenkohl, Anja
Schröter, Romy
Finter, Constanze
Siem, Anna-Katharina
Tlach, Lisa
Werkle, Nathalie
Bargel, Susann
Ohm, Gunda
Hoff, Martin
Peter, Helmut
Scherer, Martin
Mews, Claudia
Pruskil, Susanne
Lüke, Johannes
Härter, Martin
Dirmaier, Jörg
Schulte-Markwort, Michael
Löwe, Bernd
Briken, Peer
Peper, Heike
Schweiger, Michael
Mösko, Mike
Bock, Thomas
Wittzack, Martin
Meyer, Hans-Jochim
Deister, Arno
Michels, Rolf
Herr, Stephanie
Konnopka, Alexander
König, Hannah
Wegscheider, Karl
Daubmann, Anne
Zapf, Antonia
Peth, Judith
König, Hans-Helmut
and
Schulz, Holger
2020.
Study protocol for a randomised controlled trial evaluating an evidence-based, stepped and coordinated care service model for mental disorders (RECOVER).
BMJ Open,
Vol. 10,
Issue. 5,
p.
e036021.
Reponen, Elina J.
Dieset, Ingrid
Tesli, Martin
Mørch, Ragni H.
Aas, Monica
Vedal, Trude S. J.
Haug, Elisabeth
Drange, Ole Kristian
Steen, Nils Eiel
Hope, Sigrun
Szabo, Attila
Gohar, Sherif M.
Wedervang-Resell, Kirsten
Djurovic, Srdjan
Melle, Ingrid
Aukrust, Pål
Andreassen, Ole A.
and
Ueland, Thor
2020.
Atherogenic Lipid Ratios Related to Myeloperoxidase and C-Reactive Protein Levels in Psychotic Disorders.
Frontiers in Psychiatry,
Vol. 11,
Issue. ,